Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults von Dobrenkov, Konstantin, Ostrovnaya, Irina, Gu, Jessie, Cheung, Irene Y., Cheung, Nai-Kong V.

Volltext

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy von Ahmed, Mahiuddin, Cheung, Nai-Kong V.

Volltext

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies von Park, Jeong A, Cheung, Nai-Kong V

Volltext

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma von Park, Jeong A., Cheung, Nai-Kong V.

Volltext

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in... von CHEUNG, Nai-Kong V, CHEUNG, Irene Y, KUSHNER, Brian H, OSTROVNAYA, Irina, CHAMBERLAIN, Elizabeth, KRAMER, Kim, MODAK, Shakeel

Volltext

Key role for myeloid cells: Phase II results of anti‐GD2 antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma von Cheung, Nai‐Kong V., Cheung, Irene Y., Kramer, Kim, Modak, Shakeel, Kuk, Deborah, Pandit‐Taskar, Neeta, Chamberlain, Elizabeth, Ostrovnaya, Irina, Kushner, Brian H.

Volltext

Promise and Challenges of T Cell Immunotherapy for Osteosarcoma von Park, Jeong A, Cheung, Nai-Kong V

Volltext

Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations von Brady, Samuel W., Liu, Yanling, Ma, Xiaotu, Gout, Alexander M., Hagiwara, Kohei, Zhou, Xin, Wang, Jian, Macias, Michael, Chen, Xiaolong, Easton, John, Mulder, Heather L., Rusch, Michael, Wang, Lu, Nakitandwe, Joy, Lei, Shaohua, Davis, Eric M., Naranjo, Arlene, Cheng, Cheng, Maris, John M., Downing, James R., Cheung, Nai-Kong V., Hogarty, Michael D., Dyer, Michael A., Zhang, Jinghui

Volltext

MicroRNA miR-29 Modulates Expression of Immunoinhibitory Molecule B7-H3: Potential Implications for Immune Based Therapy of Human Solid Tumors von HONG XU, CHEUNG, Irene Y, GUO, Hong-Fen, CHEUNG, Nai-Kong V

Volltext

Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies von Hoseini, Sayed Shahabuddin, Cheung, Nai-Kong V

Volltext

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response von Park, Jeong A., Wang, Linlin, Cheung, Nai-Kong

Volltext

Immunotherapy with anti‐GD2 monoclonal antibody in infants with high‐risk neuroblastoma von Kushner, Brian H., Modak, Shakeel, Kramer, Kim, Basu, Ellen M., Iglesias‐Cardenas, Fiorella, Roberts, Stephen S., Cheung, Nai‐Kong V.

Volltext

Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3 von Ahmed, Mahiuddin, Cheng, Ming, Zhao, Qi, Goldgur, Yehuda, Cheal, Sarah M., Guo, Hong-Fen, Larson, Steven M., Cheung, Nai-Kong V.

Volltext

Neuroblastoma: developmental biology, cancer genomics and immunotherapy von Cheung, Nai-Kong V., Dyer, Michael A.

Volltext

Treatment and outcome of adult‐onset neuroblastoma von Suzuki, Maya, Kushner, Brian H., Kramer, Kim, Basu, Ellen M., Roberts, Stephen S., Hammond, William J., LaQuaglia, Michael P., Wolden, Suzanne L., Cheung, Nai‐Kong V., Modak, Shakeel

Volltext

Stage 4N neuroblastoma before and during the era of anti‐GD2 immunotherapy von Kushner, Brian H, LaQuaglia, Michael P, Fiorella Iglesias Cardenas, Basu, Ellen M, Gerstle, Justin T, Kramer, Kim, Roberts, Stephen S, Wolden, Suzanne L, Nai‐Kong V Cheung, Modak, Shakeel

Volltext

KMT2A‐MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8‐year follow‐up von Felix, Carolyn A., Slater, Diana J., Davenport, James W., Yu, Xiang, Gregory, Brian D., Li, Marilyn M., Rappaport, Eric F., Cheung, Nai‐Kong V.

Volltext

Targets and Antibody Formats for Immunotherapy of Neuroblastoma von Park, Jeong A., Cheung, Nai-Kong V.

Volltext

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study von Modak, Shakeel, Kushner, Brian H., Basu, Ellen, Roberts, Stephen S., Cheung, Nai‐Kong V.

Volltext

Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy von Cheung, Nai-Kong V, Ostrovnaya, Irina, Kuk, Deborah, Cheung, Irene Y

Volltext